Basic Neurosciences · Paper A
Dementia neuropathology
Each dementia has a specific microscopic finding, and matching the finding to the disease is one of the most reliably tested facts in this area. For example, imagine looking down a microscope at brain tissue and seeing sticky protein clumps outside the cells alongside twisted fibres inside them. In practice, memorising these pathology-disease pairs pays off directly in exam questions.
Alzheimer's disease shows extracellular beta-amyloid plaques (sticky protein clumps outside cells) together with intracellular neurofibrillary tangles, made of a twisted, hyperphosphorylated (over-modified) form of the tau protein. Dementia with Lewy bodies and Parkinson's disease share a different finding: intracytoplasmic alpha-synuclein Lewy bodies, protein clumps inside the cell body. Pick's disease, a type of frontotemporal dementia, shows tau-positive Pick bodies instead. Creutzfeldt-Jakob disease shows spongiform change (a sponge-like appearance) with abnormal prion protein. Huntington's disease shows atrophy (shrinkage) of the striatum, a deep brain structure. For example, imagine a pathology report describing spongiform change and abnormal prion protein. In practice, this means the specific microscopic finding, not the clinical symptoms alone, gives the definitive diagnosis.
Dementia is an umbrella clinical term for progressive decline in cognitive function severe enough to impair daily functioning, but the word covers several genuinely different underlying diseases. Each of the major dementias has a specific, microscopically identifiable pathological signature, and matching finding to disease is one of the most reliably testable facts in this area of psychiatry. For a fresh graduate, the value of learning these pathology-disease pairings goes beyond exam technique: it explains why different dementias progress differently, respond to different treatments, and sometimes require different diagnostic pathways, including brain imaging and, occasionally, tissue diagnosis.
Neuropathology, here, means the specific, microscopic disease process happening inside brain tissue: the abnormal protein deposit or tissue damage a pathologist could actually point to under a microscope or on a scan. Dementia itself is the clinical syndrome (the pattern of symptoms a patient and family notice: memory loss, personality change, disorientation); neuropathology is the hidden biological cause sitting underneath that syndrome. Several different neuropathologies can produce a similar-looking clinical syndrome, which is exactly why pathology matters for getting the diagnosis right.
The trap most beginners fall into is assuming you can reliably tell the dementia subtype from symptoms alone. You mostly cannot. Memory loss, disorientation, and personality change overlap heavily across Alzheimer's disease, vascular dementia, frontotemporal dementia, and Lewy body dementia, especially early on. The pathology is what is genuinely different between them, and it is the pathology, not the surface symptom pattern, that should drive your thinking about prognosis and treatment safety, most obviously the antipsychotic of Lewy body dementia, discussed below, which can be life-threatening if the subtype is missed.
Neurons (brain cells) depend on two things working properly: an internal skeleton that keeps their shape and allows transport of materials along their long processes, and clear signalling between cells. Several dementias arise because a specific protein misfolds, changes its normal three-dimensional shape into an abnormal, sticky, aggregation-prone form, and then accumulates either inside or outside neurons, disrupting one or both of those functions. Crucially, which protein misfolds, and where it accumulates, differs by disease, and that difference is what produces the distinct clinical patterns and distinct microscopic findings described below. Vascular dementia is the exception to this "misfolded protein" logic: its damage comes from interrupted blood supply, not protein accumulation, which is why it behaves differently both pathologically and clinically.
Alzheimer's disease, the commonest cause of dementia, shows two hallmark findings on microscopy: extracellular amyloid-beta plaques, sticky protein clumps that sit outside neurons, and intracellular neurofibrillary tangles, twisted bundles made of hyperphosphorylated tau, an abnormally over-modified form of the tau protein that normally supports the internal skeleton of neurons. For example, imagine a pathologist examining brain tissue from a patient who died with a long history of progressive memory loss; finding both amyloid plaques between cells and tau tangles within cells confirms Alzheimer's pathology specifically, rather than another dementia subtype.
Dementia with Lewy bodies and Parkinson's disease share a different pathological signature: intracytoplasmic alpha-synuclein Lewy bodies, abnormal protein clumps that form inside the cell body rather than outside it. This shared pathology explains why the two conditions overlap clinically, with parkinsonian motor features, fluctuating cognition, and visual appearing across both.
Frontotemporal dementia is pathologically heterogeneous, with abnormal tau or TDP-43 protein deposits underlying most cases; Pick's disease, a specific subtype, shows tau-positive Pick bodies on microscopy. Clinically, frontotemporal dementia often presents earlier than Alzheimer's, with prominent personality and behavioural change rather than memory loss as the leading symptom.
Vascular dementia is not a single protein-deposition disease at all: its pathological substrate is cerebral infarcts, areas of brain tissue damaged by interrupted blood supply, often producing a stepwise rather than smoothly progressive cognitive decline. Consider a patient whose cognitive decline occurred in sudden drops corresponding to documented small strokes rather than gradual deterioration; this pattern, together with vascular risk factors, points toward vascular dementia over Alzheimer's.
Huntington's disease is a genetic, inherited neurodegenerative condition causing a distinctive triad of chorea (involuntary, jerky movements), cognitive decline, and psychiatric symptoms. Its pathological hallmark is atrophy, meaning tissue shrinkage, of the caudate nucleus, part of the deep brain structure called the striatum.
Several conditions mimic each other closely enough to trip up a fast reader. Alzheimer's versus vascular dementia: Alzheimer's declines smoothly and gradually, while vascular dementia classically declines in sudden steps tied to vascular events, with vascular risk factors (hypertension, diabetes, smoking) in the history. Alzheimer's versus frontotemporal dementia: Alzheimer's usually presents later in life with memory loss first, whereas frontotemporal dementia often presents younger (before 65) with personality and behavioural change first, memory relatively preserved early on. Lewy body dementia versus Parkinson's disease dementia: both share alpha-synuclein pathology, and the accepted rule of thumb is timing: if cognitive decline appears within a year of parkinsonian motor symptoms starting, call it Lewy body dementia; if motor symptoms have been established for over a year before cognitive decline appears, call it Parkinson's disease dementia. Dementia versus delirium: delirium (an acute confusional state) comes on over hours to days, fluctuates through the day, and often has an identifiable trigger such as infection, whereas dementia develops over months to years and is comparatively stable day to day. This distinction matters because delirium is frequently reversible and a missed delirium is a dangerous error. Finally, depression can produce a "pseudodementia" picture in older adults, with poor concentration and apparent memory loss; a helpful clue is that depressed patients often say "I don't know" to test questions, while genuine dementia patients tend to attempt an answer and get it wrong.
Diagnosing dementia, and pinning down its subtype, rests on several converging strands rather than any single test. Cognitive screening tools such as the MMSE () or the MoCA (Montreal Cognitive Assessment) quantify the degree of cognitive impairment and track change over time. A collateral history from a family member is essential, since patients themselves may lack into their own decline. Blood tests are routinely used to exclude reversible mimics: thyroid dysfunction, vitamin B12 deficiency, before settling on a neurodegenerative diagnosis. Structural imaging with CT or MRI helps both to exclude alternative causes (a tumour, chronic subdural haematoma) and to support the subtype: hippocampal atrophy favours Alzheimer's, multiple infarcts favour vascular dementia. Functional imaging, such as a DaTscan (a scan that images dopamine transporters), can help confirm Lewy body dementia when the picture is unclear. Genetic testing provides definitive diagnosis in Huntington's disease, which follows an autosomal dominant inheritance pattern with a known causative gene. Formal diagnostic criteria, drawing on ICD-11 or DSM-5, are then applied to the whole clinical and investigative picture; definitive pathological confirmation is typically reserved for post-mortem examination.
First-line management, per NICE NG97, begins with non-pharmacological measures such as cognitive stimulation therapy and support for carers, alongside optimising any reversible contributing factors. For Alzheimer's disease specifically, NICE NG97 recommends cholinesterase inhibitors (drugs that boost the acetylcholine by blocking its breakdown) such as donepezil for mild to moderate disease, and memantine, an NMDA-receptor , for moderate to severe disease or where cholinesterase inhibitors are unsuitable. Vascular dementia management centres on aggressive control of vascular risk factors: blood pressure, cholesterol, antiplatelet therapy where indicated, since there is no dedicated drug treatment for the vascular pathology itself. Frontotemporal dementia has no specific licensed pharmacological treatment; management is largely supportive, with behavioural strategies and carer support. The single most safety-critical management point across all subtypes concerns Lewy body dementia: patients can develop severe, sometimes life-threatening reactions to antipsychotic medication, so any consideration of antipsychotics for or agitation requires particular caution and specialist input.
The classic exam trap is a patient with visual , fluctuating cognition, and parkinsonism who is prescribed a standard antipsychotic for the hallucinations and develops a severe reaction. The question is testing whether you recognised Lewy body dementia from the triad before reaching for the prescription pad. The second most tested fact is the pathology-disease pairing itself: amyloid plaques and tau tangles for Alzheimer's, alpha-synuclein Lewy bodies for Lewy body dementia and Parkinson's, tau or TDP-43 for frontotemporal dementia, infarcts for vascular dementia, caudate atrophy for Huntington's.
A definitive dementia diagnosis ultimately rests on pathology: amyloid plaques and tau tangles, alpha-synuclein Lewy bodies, tau/TDP-43, infarcts, or caudate atrophy, because the clinical pictures overlap too much to trust symptoms alone, and getting the subtype right directly changes both prognosis and the safety of treatment choices.